Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Onchilles Pharma Secures $25M Series A1 Funding to Advance Cancer Therapeutic
Series AVenture Capital

Onchilles Pharma Secures $25M Series A1 Funding to Advance Cancer Therapeutic

•November 10, 2025
•Nov 10, 2025
0

Participants

Onchilles Pharma

Onchilles Pharma

company

Kennedy Lewis

Kennedy Lewis

investor

Lincoln Park Capital

Lincoln Park Capital

investor

UChicago Medicine

UChicago Medicine

investor

InVivium

InVivium

investor

Why It Matters

The infusion of capital speeds development of a novel ELANE‑targeted cancer therapy with broad preclinical efficacy, enhancing Onchilles' prospects for clinical success and signaling strong investor confidence in the biotech sector.

Deal Summary

Onchilles Pharma announced a $25 million Series A1 financing to push its lead ELANE‑target injectable, N17350, into clinical proof‑of‑concept studies. The round attracted new investors Invivium Capital, Kennedy Lewis Investment Management and UCM Ventures, alongside existing backers LYZZ Capital Advisors and Lincoln Park Capital Fund.

0

Comments

Want to join the conversation?

Loading comments...